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Much research has surrounded the use of monoclonal antibody
(mAb)–enzyme conjugates for the activation of anticancer
prodrugs (Melton and Sherwood, 1996; Niculescu-Duvaz and
Springer, 1996; Senter and Svensson, 1997). This is a two-step
approach to drug delivery in which a mAb–enzyme conjugate that
specifically localizes into solid tumour masses is administered,
followed by systemic treatment with an anticancer prodrug. Upon
contact with the targeted enzyme, the prodrug is converted into an
active cytotoxic drug. The advantages of this targeting strategy
over the use of covalently linked mAb–drug conjugates (Pietersz
et al, 1994) for selective drug delivery are that a single localized
mAb–enzyme conjugate is capable of catalytically generating
large amounts of active drug, and the drug thus formed can
penetrate into regions of the tumour mass that are inaccessible to
the conjugate. Pharmacokinetics studies have demonstrated that
mAb–enzyme/prodrug combinations can result in high intra-
tumoural drug concentrations (Bosslet et al, 1994; Wallace et al,
1994; Svensson et al, 1995), and pronounced anti-tumour activi-
ties in an array of preclinical tumour models (Springer et al, 1991;
Meyer et al, 1993; Eccles et al, 1994; Kerr et al, 1995; Siemers
et al, 1997) and in a small scale clinical trial have been reported
(Bagshawe and Begent, 1996).
A number of critical issues must be addressed to assure optimal
therapeutic efficacy with this targeting strategy. In order to mini-
mize systemic non-targeted drug release, a high mAb–enzyme
tumour to normal tissue ratio is needed before the prodrug is
administered. The time required for this to occur varies among the
many mAb-enzyme/prodrug systems reported. For example, in
nude mouse models for human cancer, the delay between conjugate
and prodrug administration was 12 h for the recombinant
L49-sFv-bL fusion protein (molecular mass 66.5 kDa) (Siemers et
al, 1997), 3 days for 96.5-Fab´-bL (molecular mass 92 kDa) (Kerr
et al, 1995), 1 week for the anti-CEA-Fab-b-glucuronidase fusion
protein (molecular mass 250 kDa) (Bosslet et al, 1994) and 2
weeks for the ICR12-carboxypeptidase G2 (molecular mass
233–316 kDa) (Eccles et al, 1994). Further critical parameters
include the absolute amount of conjugate that localizes within the
tumour mass, the enzyme kinetic parameters (Km and kcat values)
for the prodrug substrate, and the amount and potency of the drug
that is released intratumourally.
Recognizing the degree of complexity inherent in this
approach, Jain and co-workers have developed a model designed
to predict the effects of conjugate distribution and enzyme kinetic
parameters on intratumoural and systemic drug concentrations
(Baxter et al, 1992; Baxter and Jain, 1996). This model provides a
theoretical underpinning for the need to have high tumour to
blood conjugate ratios before prodrug is administered. Since
residual mAb–enzyme conjugate in the blood will lead to
systemic drug release, the model of Baxter and Jain leads to the
prediction that for a particular prodrug, activating enzymes with
relatively higher Km and lower kcat values would be expected to
provide higher intratumoural drug concentrations.
Based on the fact that conjugate tumour localization and reten-
tion is critical for the therapeutic efficacy in many mAb-based
targeting strategies including the one described here, we wished
to determine which of the many possible critical issues are
most influential. This work describes a mathematical model that
analyses the effects that many of the physiological and biochem-
ical parameters have on intratumoural uptake of a mAb–enzyme
conjugate. The model suggests that vascularity and the kinetics of
conjugate dissociation from tumour antigens are critical deter-
minants for intratumoural conjugate localization and retention.
Experiments are presented that provide validation for this mathe-
matical model.
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Summary Considerable research has been aimed at improving the efficacy of chemotherapeutic agents for cancer therapy. A promising two-
step approach that is designed to minimize systemic drug toxicity while maximizing activity in tumours employs monoclonal antibody
(mAb)–enzyme conjugates for the activation of anticancer prodrugs. We present, analyse and numerically simulate a mathematical model
based on the biology of the system to study the biodistribution, pharmacokinetics and localization properties of mAb–enzyme conjugates in
tumour tissue. The model predictions were compared with experimental observations and an excellent correlation was found to exist. In
addition, the critical parameters affecting conjugate half-life were determined to be the inter-capillary half-distance and the antibody–antigen
binding affinity. An approximation is presented relating the per cent injected dose per gram to inter-capillary half-distance and time. Finally, the
model was used to examine various dosing strategies in an attempt to determine which regimen would provide the best biodistribution results.
We compared the results of administering a uniform dose of fusion protein via bolus injection, multiple injections and continuous infusion. The
model predicts that dosing strategy has little effect on the amount of conjugate that localizes in the tumour.
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Expression of L49-sFv-bL
L49-sFv-bL, which is comprised of the single chain Fv fragment
of the L49 antibody fused to a mutated form of Escherichia
cloacae bL, was expressed in E. coli and purified from culture
supernatants as previously described (Siemers et al, 1997). Briefly,
the E. coli strain BL21(lDE3) was transformed with the plasmid
encoding L49-sFv-bL fused to the pelB leader sequence. The gene
orientation was pelB-VH-218 linker-VL-bL. Soluble expression of
L49-sFv-bL was accomplished at 23°C with 0.05 mM isopropyl
b-D-thiogalactopyranoside to induce protein expression. The
fusion protein was purified from the culture supernatant using a
two-step affinity purification technique involving binding of the
L49 portion of the protein to immobilized p97 antigen, followed
by binding of the bL portion to immobilized phenylboronic acid.
The protein obtained in this manner was pure by sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and
retained the the activities of both the L49 and the bL moieties.
Surface plasmon resonance experiments were performed on a
BIAcore 2000 instrument (Pharmacia) as previously described
(Siemers et al, 1997). The results from four independent experi-
ments led to association and dissociation, ka and kd respectively,
values of 3.88 ´ 105 M–1 s–1 and 4.83 ´ 10–4 s–1 respectively.
Conjugate localization
The 3677 melanoma tumour line (Kerr et al, 1995) was implanted
subcutaneously into the flanks of female athymic nu/nu mice
(8–12 weeks old, Harlan Sprague-Dawley, Indianapolis, IN, USA)
and were allowed to grow for 8–10 days, at which time the
tumours were approximately 150 mm3 in volume. The mice were
injected with L49-sFv-bL (1.33 mg kg–1 injection–1 at 4-h intervals
for three doses, or 4 mg kg–1 in a single dose), and at various time
intervals, the mice were anaesthetized, bled through the orbital
plexus and sacrificed. The tumours were removed, weighed
and homogenized in phosphate-buffered saline (PBS), pH 7.2,
containing 15 mg ml–1 aprotinin (2 ml g–1 of tissue). To the
homogenate was added 50 mM sodium phosphate containing
100 mM sodium chloride at pH 11.2 (10 ml g–1 of tissue), and the
suspension was mixed. After 20 min at room temperature, 3 M
sodium phosphate at pH 7.0 were added (2 ml g–1 of tissue), and
the mixture was mixed and centrifuged.
Quantification of conjugate concentration was accomplished by
determining the bL activity in the tumours of treated mice
compared to untreated control tumours, and tumours that were
spiked with known quantities of L49-sFv-bL just prior to extrac-
tion. Polystyrene 96-well microtitre plates were coated with an
affinity-purified rabbit polyclonal antiserum to wild-type E.
cloacae bL (1 mg ml–1, and were then blocked with specimen
diluent (Genetic Systems Corp., Seattle, WA, USA). Serially
diluted tissue extracts or purified samples were added to the wells
and allowed to bind for 3 h at room temperature. The plates were
washed with specimen diluent and were developed by adding
0.1 ml of nitrocefin (O’Callaghan et al, 1972) at 0.1 mM in PBS,
pH 7.2, containing 1% dimethylformamide. Absorbance measure-
ments were read in an enzyme-linked immunosorbent assay
(ELISA) plate reader using a 490 nm filter with 630 nm as the
reference wavelength.
Model
The mathematical model is based on the conception of the tumour
as equivalent to a collection of cylinders of tissue, each nourished
by a single capillary, the collection possessing the same structure
as a box of pencils (Krogh, 1919). Each Krogh cylinder is consid-
ered to have an outer radius L equal to half the average distance
between capillary centres and an inner radius r equal to the
average radius of the tumour capillaries.
The pharmacokinetics outside the tumour is modelled by two
well-mixed compartments, the plasma compartment and the
peripheral compartment representing all other non-tumour, non-
plasma tissues. The fusion protein is injected directly into the
plasma compartment and distributes throughout via reversible
transfer between the plasma and peripheral compartments. The
fusion protein can only be eliminated from the system while in the
plasma compartment and only from here can it pass through the
microvessel wall and enter the tissue. The tissue is considered to
be homogeneous, that is the intracellular and extracellular space is
considered to be one unit. Once in the tissue compartment the
fusion protein is free to diffuse or to bind to antigens presented on
cell surfaces. Since the fusion protein has an isoelectric point near
neutrality (Siemers et al, 1997), we have not factored in the effect
of protein net charge on biodistribution and clearance.
The usual compartment approach yields the mathematical
model of Baxter and Jain (1996) which describes the rate of
change of the concentration of free and bound fusion protein in the
tumour, plasma and peripheral compartments. The variables that
are tracked are listed in Table 1 along with the parameters that
govern their rates of change.
In the microvessel, the concentration of conjugate, p1, satisfies
dp1 =–k12p1 + k21 p2 – kep1 + I(t)
dt
Rate of change        Transfer Out + Transfer In – Elimination
of fusion protein =   + Dosing
In the peripheral compartment, the concentration of conjugate,
p2, satisfies
dp2 = k12p1 – k21 p2 dt
Rate of change
of fusion protein 
= Transfer In – Transfer Out
In the tissue, the concentrations of free conjugate, FF, and bound
conjugate, FB, are governed by
¶FF = DFDFF – kaFF(A0 – FB)+kdFB ¶t
Rate of change of 
free fusion protein 
= Diffusion – Binding + Dissociation
¶FB = kaFF(A0 – FB)–kdFB ¶t
Rate of change of 
bound fusion protein 
= Binding – Dissociation
where D is the cylindrically symmetric Laplacian operator in three
dimensions (D = ¶2
¶r2 + 1
r
¶
¶r).
The initial concentration of fusion protein in each compartment
must be given and boundary conditions governing the behaviour at
the boundaries must be prescribed to complete the model. Initially,
the concentration of both free and bound fusion protein in the
tumour is zero:
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FB(r, 0) = 0
The initial concentration of fusion protein in the plasma
compartment is the administered dose, F0, and there is no fusion
protein in the peripheral compartment initially:
p1(0) = F0
p2(0) = 0
Due to symmetry with surrounding Krogh cylinders, the net flux
across the tissue boundary, r = L, is zero:
¶FF (L,t) = 0 ¶r
The flux across the blood vessel wall, r = r, is driven by the
concentration difference in the two compartments and by the wall
permeability.
¶FF (r,t) = –
P
[F1(t) – FF(p,t)] ¶r                 DF
The mathematical model equations were solved by computer
simulation, using a finite difference scheme and different experi-
mental scenarios were tested.
Data analysis
By incorporation of the experimental data, a least-squares fit for
the plasma clearance of the fusion protein, L49-sFv-bL (Siemers et
al, 1997), into the biexponential function C = Ae—at + Be—bt was
obtained and values for A, B, a, b were determined. These values
were in turn used to compute the compartmental transfer coeffi-
cients k12, k21 and ke. The diffusion coefficient, DF, was assumed to
depend on the molecular weight, MW as a(MW)b using published
values for a and b (Nugent and Jain, 1984). To compute the antigen
density, A0, the average value of the number of molecules per cell
when saturated was 2.1 ´ 104 molecules
cell . The cell density was esti-
mated as 2.83 ´ 1011 cell
litre (Baxter and Jain, 1991) by assuming 50%
cell fraction and an average cancer cell diameter of 15 mm (cell
density = 
cell fraction
(
4
3)pr
3 ). Together these values lead to the antigen
density listed in Table 2. The average distance between capillary
centres was calculated as L = Ö
0.25
pN where N is the average number
of capillaries in every 0.25 mm2 of tissue. N was determined exper-
imentally on parafirmaldehyde fixed tumours that were embedded
in paraffin.
RESULTS
We calculated the per cent injected dose of conjugate per gram of
tumour tissue as the average in a complete Krogh cylinder at a
given time post-injection of conjugate. Model parameters were
varied to determine which were most influential for the localiza-
tion and retention of conjugate within the tumour mass.
Dependence on tumour vasculature
In a poorly vascularized section of the tumour, the Krogh cylinders
are large and each microvessel must supply more of the
surrounding tissue. As a result the per cent injected dose per gram
observed in the tumour at a given time after injection decreases
rapidly with Krogh cylinder size (Figure 1A). The dependence of
the per cent injected dose at a given time post-injection, on the
Krogh cylinder size or inter-capillary half-distance, L, was found
to follow a power law. There is approximately a straight-line fit
(with slope m < 0) of the log–log plot of per cent injected dose vs.
L in the experimentally determined range of L (shaded regions,
Figure 1B). Thus we can write
% Injected dose = m0Lm(t)
where m1(t) is the time-dependent slope of the line in Figure 1B,
which was found to vary linearly with time. That is m(t) = m1 +
m2t. This leads to an exponential decrease in the per cent injected
dose over time, and we can write
% Injected dose = Pe—mt
where P = P(L) = m0Lm1 and m = m(L) = –m2log(L). Given the
parameter values in Table 2, we find m1 = –2.2, m2 = 0.037, and
m0 = 0.015. Figure 2 compares this asymptotic approximation
(Jackson et al, manuscript in preparation) to the numerical solution.
Critical parameters
We investigated the effect of each parameter of the model on the
elimination rate, m, of fusion protein in the tumour by calculating
E = 
m2 – m1/2
m1 . Here, m1 is the elimination rate when all parameters have
the values listed in Table 2 and m1/2 and m2 are the elimination rates
associated with reducing by half and doubling each parameter
respectively (Table 3). The baseline m1 for parameters in Table 2
was 0.076 h–1 representing a half-life of 9.12 h. The parameters
that have the greatest effect on the conjugate retention in the
tumour are the inter-capillary half-distance, L, the antigen associa-
tion/dissociation rates, ka, kd, the initial concentration of binding
sites A0, and the permeability, P.
If L is small corresponding to a well vascularized section of the
tumour, the half-life is significantly shorter than when L is large
corresponding to a poorly vascularized section of tissue.
Deceasing the dissociation ratio, 
kd
kaA0, will also significantly
decrease the tumour elimination rate; and decreasing the perme-
ability ratio, 
P
L, will have similar effects.
Correlation between the mathematical model and the
experimental data
The biodistribution of L49-sFv-bL in nude mice bearing subcuta-
neous 3677 melanoma xenografts has previously been reported
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Table 1 Definition of variables and parameters of the model
Variable Definition
FF(r,t) Concentration of free fusion protein in the tissue (M)
FB(r,t) Concentration of bound fusion protein in the tissue (M)
p1(t) Concentration of fusion protein in the plasma (M)
p2(t) Concentration of fusion protein in the peripheral 
compartment (M)
Parameter Definition
F0 Initial concentration of fusion protein (M)
k12, k21 Compartmental transfer coefficients (s–1)
ke Plasma elimination rate (s–1)
L Krogh cylinder radius (mm)
r Microvessel radius (mm)
P Permeability coefficient of the microvessel wall (mm s–1)
DF Diffusion coefficient of fusion protein in tissue (mm2 s–1)
ka, kd Association and dissociation rate (M–1 s–1, s–1)
A0 Antigen density (M)(Siemers et al, 1997). In these studies, L49-sFv-bL was adminis-
tered as a single bolus intravenous injection at doses of either
1 mg kg–1 or 4 mg kg–1. At various time points, tumours and blood
were removed, and bL activity was used to assess conjugate
concentration. The data from the experiments in which animals
received 1 mg kg–1 L49-sFv-bL are shown in Figure 3. This Figure
also shows the results of the mathematical model simulations
using the parameters listed in Table 2.
An excellent correlation exists between the model and the
experimental data, both for the L49-sFv-bL concentrations in the
tumour (Figure 3A) and in the plasma (Figure 3B). Table 4 shows
this correlation.
Effect of injection schedule on fusion protein
localization
In order to determine the best dosing strategy for fusion protein
localization, the results of administering a uniform dose of fusion
protein via bolus injection, multiple injections and continuous
infusion were simulated. For the bolus strategy, the injection of a
single dose of 4
mg
kg was numerically simulated and the level of
fusion protein in the tumour and plasma were calculated 24 h later.
For the multiple injection strategy, the administration of three
equal doses of 1.33
mg
kg at 4-h intervals was simulated so that the
total amount injected was 4
mg
kg. Twenty-four hours after the initial
injection, the levels of fusion protein in the tumour and the plasma
were calculated. Finally, continuous infusion of 4
mg
kg over an 8-h
period was simulated, again computing the tumour and plasma
levels 16 h after the end of dosing. The per cent injected dose of
conjugate per gram of tumour for all three strategies as determined
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Figure 1 Percent injected dose of fusion protein per gram of tumour tissue at t = 4 h vs Krogh cylinder size (A), (B) and a log–log plot of the same information.
Shaded regions in (A) and (B) correspond to the range of inter-capillary half-distances, L, as experimentally determined for the 3677 line
Table 2 List of baseline parameter values used in simulations
Parameter Value Reference
L 0.11 mm Materials and Methods
r 0.002 mm Materials and Methods
F0 1.2 ´ 10–7 M (Siemers et al, 1997)a
k12 2.4 ´ 10–5 s–1 (Siemers et al, 1997)b
k21 5.8 ´ 10–4 s–1 (Siemers et al, 1997)b
ke 7.1 ´ 10–5 s–1 (Siemers et al, 1997)b
DF 8.0 ´ 10–6 mm2s–1 (Baxter and Jain 1991)
ka 3.88 ´ 105 M–1 s–1 Materials and Methods
kd 4.83 ´ 10–4 s–1 Materials and Methods
P 9.0 ´ 10–5 mm s–1 (Baxter and Jain, 1996)
A0 1.0 ´ 10–8 M (Baxter and Jain 1991; Siemers et al, 1997)
a Based on an injection of 1 mg kg–1 conjugate (Mw = 63 kDa) and a blood
volume of 2.5 ml. b A least-squares fit for the plasma clearance of L49-sFv-bL
(Siemers et al, 1997), was used to compute the compartmental transfer
coefficients and the plasma elimination rate, k12, k21 and ke.
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Figure 2 Per cent injected dose of fusion protein per gram of tumour tissue
vs time as predicted by the mathematical model (solid line) and the
asymptotic approximation to this solution (dashed line)experimentally and by mathematical model simulations are
comparable (Table 5). However, a significant difference was found
for the amount of conjugate remaining the plasma in animals that
received multiple conjugate injections. In this dosing regimen, the
mathematical model predicts that 0.002% of the injected dose
should be found in the plasma, but the amount found was four
times higher (0.008% injected dose per gram). The reason for this
apparent discrepancy is likely due to our inability to quantify
exceedingly small amounts of conjugate with the enzyme assay
that was utilized for conjugate quantitation. With this limitation in
mind, the simulations and experimental data are in general agree-
ment, and lead to the conclusion that the dosing strategy does not
play a critical role in the amount of conjugate that is taken up
within the tumour. There would be little advantage in partitioning
the L49-sFv-bL dose compared to giving the conjugate in a bolus
injection.
DISCUSSION
There are many factors that can influence intratumoural localiza-
tion and systemic clearance of macromolecular conjugates (Baxter
and Jain, 1989, 1991). Included among them are tumour vascu-
larity and intrastitial pressure, diffusion of the conjugate out of the
vasculature, and conjugate molecular weight and blood clearance
characteristics. Once the conjugate gains access to the tumour
mass, distribution and retention can be affected by antigen distrib-
ution, conjugate association and dissociation rates, and processing
of the conjugate once it becomes bound to the tumour cells. The
net result is that therapeutic optimization studies are generally
empirical and quite laborious. For example, in the
mAb–enzyme/prodrug strategy, the administration of prodrug
following conjugate treatment has ranged from 12 h for a fast
clearing sFv fusion protein (Siemers et al, 1997), to 2 weeks for a
slow clearing whole mAb conjugate (Eccles et al, 1994). It is
significant that none of the published in vivo examples of this
particular targeting strategy have been subject to rigorous experi-
mental optimization. This is due to the large number of parameters
involved. As a result, mathematical models that shed insight into
how best in vivo experiments can be carried out are of great value.
The original model for the mAb–enzyme prodrug targeting
strategy was described by Jain and co-workers (Jain et al, 1992,
1996). These investigators regarded the biological system as being
comprised of three compartments, the blood pool, the tumour and
the remaining tissues. A set of equations was generated from such
parameters and variables as those listed in Table 1. The focus of
developing this model was to delineate the main contributing
factors for achieving high intratumoural drug concentrations,
which were concluded to be the conjugate tumour/blood ratio and
Analysis of conjugate localization 1751
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Table 3 The effect of each parameter on the elimination rate, m, in the
tumour
Parameter Value m1/2 (h–1)a m2 (h–1)a Eb
D 8.0 ´ 10–6 mm2 s–1 0.075 0.077 0.031
ka 3.88 ´ 105 M–1 s–1 0.14 0.04 –1.3
kd 4.83 ´ 10–4 s–1 0.040 0.14 1.3
A0 1.0 ´ 10–8 M 0.14 0.04 –1.3
k12 2.4 ´ 10–5 s–1 0.077 0.074 –0.034
k21 5.8 ´ 10–4 s–1 0.072 0.078 0.068
ke 7.1 ´ 10–5 s–1 0.076 0.075 –0.010
P 9.0 ´ 10–6 mm s–1 0.04 0.15 1.5
L 0.10 mm 0.16 0.036 –1.7
r 0.010 mm 0.073 0.083 0.12
F0 1.0 mg/kg 0.076 0.076 0
am1/2 and m2 are the decay rates associated with reducing by half and
doubling, respectively, the specific parameter listed. bTo measure the effect of
each parameter on the elimination rate of the fusion protein in the tumour, the
ratio E = m2 – m1/2/m1 was computed, where m1 = 0.076 is the elimination rate
when all parameters have their baseline values. The larger the deviation from
zero, the more significant the parameter.
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Figure 3 Mathematical model simulation of conjugate localization in tumour tissue (A) and plasma (B) compared with the experimental findings reported by
Siemers and co-workers (Siemers et al, 1997). The model data using a value of 0.11 mm for L correlates with the experimentally determined datathe enzyme kinetic parameters, Km and Vmax. We wished to expand
upon this model and to focus specifically on the parameters that
affected intratumoural conjugate uptake, retention and localization
index. A secondary aspect of the work was to use the model to
predict the effects of various conjugate dosing strategies.
Of all the parameters considered, tumour vasculature, vessel
permeability and the conjugate dissociation ratio,
kd
kaA0, were most
important in determining conjugate localization. The model we
describe predicts that increases in the inter-capillary half-distance,
L, will decrease the concentration of conjugate in the tumour as a
power law. Retention of conjugate in the tumour mass is most
significantly influenced by the rate of association and dissociation
from cell-surface antigens. Reducing the conjugate dissociation
ratio by 50% will double the half-life in the tumour. The model
therefore predicts that the highest intratumoural conjugate
localization will involve high affinity mAbs that target well-
vascularized tumours.
The model was validated experimentally and an excellent corre-
lation was found to exist between the model predictions and the
experimental data (Figure 3). The comparison made in Figure 3
does not represent a least-squares parameter-optimizing curve fit
to the localization data, but rather represents simulations using
fixed parameters estimated from other experiments. The model
enabled us to make predictions concerning the differences that
would be expected if the conjugate was administered in a single
bolus injection, in partitioned doses, or as a continuous infusion.
The model predicted that the three dosing regimens would yield
roughly the same intratumoural conjugate concentrations. This
was confirmed experimentally for both bolus and multiple injec-
tion strategies (Table 5).
The mathematical approach and the general conclusions from
this work can be applied to other macromolecules that bind to
receptors in solid tumour masses. The critical information
needed to use the model include knowledge of the plasma clear-
ance rates, the binding constants, and the average inter-capillary
half-distance. Using this model, it is possible to predict the total
amount of conjugate that will bind and the amount within a
tumour at a given time post-injection. This information will prove
useful in designing optimal dosing strategies for targeted drug
therapy. We are now extending the model to include predictions
of intratumoural drug concentrations that result after the adminis-
tration of prodrug.
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Table 4 Correlation of experimental localization data with the mathematical model
% ID g–1 Tumoura % ID g–1 Plasmaa Ratio
Time (h) Model Experiment Model Experiment Model Experiment
4 1.22 1.15 ± 0.18 0.13 0.084 ± 0.04 9.38 15.2 ± 3.5
12 0.711 0.532 ± 0.17 0.017 0.008 ± 0.002 41.8 68.7 ± 12.7
24 0.308 0.214 ± 0.02 0.001 0.002 ± 0.000 308 111 ± 26.1
aThe dose administered was 1.0 mg kg–1 for the experiments and the model simulations.
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Bolusb 0 0.31 0.29 ± 0.05 0.01 0.006 ± 0.002
Multiplec 0, 4, 8 0.41 0.32 ± 0.03 0.002 0.008 ± 0.002
Continuousd 0–8 0.41 n.d.e 0.003 N.D.e
aThe measurements and calculations were determined 24 h post-conjugate administration. bA single injection of
4 mg kg–1 was administered. cThree equal doses of 1.33 mg kg–1 injection–1 was administered. dContinuous infusion
of 4 mg kg–1 of conjugate over an 8 h period was simulated. eND, Not determined.Krogh A (1919) The number and distribution of capillaries in muscles with
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